← Leaderboards
Eddy Yang
University Of Miami School Of Medicine
$1,454,659
Attributed
$3,777,727
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,777,727 · 7
By mechanism
R01$2,266,573 · 1
UG1$1,015,024 · 1
P30$381,078 · 2
F30$108,543 · 1
M01$6,509 · 2
Top collaborators
- Xiaoguang Margaret Liu4 shared
- Lufang Zhou4 shared
- Mary-Ann Bjornsti2 shared
- Charles A. Leath2 shared
- Amitkumar N Mehta2 shared
- Erica Michelle Stringer-Reasor2 shared
Most similar at University Of Miami School Of Medicine
Same institution · by research overlap
- Gwendolyn B. Scott$31,214,415
- Margaret A Fischl$33,970,395
- Dushyantha Jayaweera$1,567,932
- Matthias A Salathe$13,653,057
Others in their field
Top investigators on “Quality Of Life”
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Gregory H Reaman · National Childhood Cancer Foundation$264,644,476
- David R. Weir · University Of Michigan At Ann Arbor$263,050,576
- Richard K. Wilson · Washington University$198,912,538
Research focus
Quality Of LifeMalignant NeoplasmsClinical TrialsTargeted TreatmentInnovationResearch PersonnelFundingNovel StrategiesInhibitorParp InhibitionEpidermal Growth Factor ReceptorFlow CytometryGrantIn VivoComprehensive Cancer CenterLeadClinicClinical ResearchAchievementBasic ScienceDrug ResistanceDna RepairAnticancer ResearchCancer Patient
Grant awards (18)
Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer$573,078
R01 · FY2025 · CA
Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer$544,425
R01 · FY2024 · CA
Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer$561,617
R01 · FY2023 · CA
02 - Experimental Therapeutics$104,385
P30 · FY2023 · CA · contact PI
Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer$587,453
R01 · FY2022 · CA
NCTN Deep South Research Consortium$482,362
UG1 · FY2022 · CA
02 - Experimental Therapeutics$104,385
P30 · FY2022 · CA · contact PI
NCTN Deep South Research Consortium$532,662
UG1 · FY2021 · CA
03 Experimental Therapeutics Program$53,231
P30 · FY2021 · CA · contact PI
03 Experimental Therapeutics Program$119,077
P30 · FY2020 · CA · contact PI
MULTICENTER TRIAL OF FETAL MYELOMINEINGOCELE REPAIR$293
M01 · FY2008 · RR · contact PI
MULTICENTER TRIAL OF FETAL MYELOMINEINGOCELE REPAIR$6,216
M01 · FY2007 · RR · contact PI
ENVIRONMENTAL ANTI-ANDROGENS AND AR AUTOREGULATION$4,837
F30 · FY2005 · ES
ENVIRONMENTAL ANTI-ANDROGENS AND AR AUTOREGULATION$23,522
F30 · FY2004 · ES
ENVIRONMENTAL ANTI-ANDROGENS AND AR AUTOREGULATION$22,718
F30 · FY2003 · ES
ENVIRONMENTAL ANTI-ANDROGENS AND AR AUTOREGULATION$20,906
F30 · FY2002 · ES
ENVIRONMENTAL ANTI-ANDROGENS AND AR AUTOREGULATION$19,000
F30 · FY2001 · ES
ENVIRONMENTAL ANTI-ANDROGENS AND AR AUTOREGULATION$17,560
F30 · FY2000 · ES